US20150292022A1 - Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy - Google Patents
Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy Download PDFInfo
- Publication number
- US20150292022A1 US20150292022A1 US14/360,804 US201214360804A US2015292022A1 US 20150292022 A1 US20150292022 A1 US 20150292022A1 US 201214360804 A US201214360804 A US 201214360804A US 2015292022 A1 US2015292022 A1 US 2015292022A1
- Authority
- US
- United States
- Prior art keywords
- nktcl
- jak3
- jak
- subject
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010042971 T-cell lymphoma Diseases 0.000 title claims abstract description 23
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 title claims abstract description 23
- 238000003745 diagnosis Methods 0.000 title abstract description 9
- 238000002560 therapeutic procedure Methods 0.000 title abstract description 6
- 210000004027 cell Anatomy 0.000 claims abstract description 76
- 230000035772 mutation Effects 0.000 claims abstract description 64
- 238000000034 method Methods 0.000 claims abstract description 51
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims abstract description 30
- 238000012360 testing method Methods 0.000 claims abstract description 30
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 28
- 210000000581 natural killer T-cell Anatomy 0.000 claims abstract description 16
- 238000010171 animal model Methods 0.000 claims abstract description 10
- 238000012216 screening Methods 0.000 claims abstract description 7
- 108091082332 JAK family Proteins 0.000 claims abstract 17
- 102000042838 JAK family Human genes 0.000 claims abstract 10
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims description 86
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims description 50
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims description 42
- 102220197883 rs121913504 Human genes 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 26
- 238000006467 substitution reaction Methods 0.000 claims description 24
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 22
- 239000002773 nucleotide Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims description 14
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims description 14
- 230000012010 growth Effects 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 101150069380 JAK3 gene Proteins 0.000 claims description 11
- 230000006907 apoptotic process Effects 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 claims description 7
- 239000002299 complementary DNA Substances 0.000 claims description 7
- 230000035899 viability Effects 0.000 claims description 7
- RYYNDHCHTCVQJH-KWWJGWKXSA-N (e)-2-cyano-3-(4-nitrophenyl)-n-[(1r)-1-phenylethyl]prop-2-enamide Chemical compound N([C@H](C)C=1C=CC=CC=1)C(=O)C(\C#N)=C\C1=CC=C([N+]([O-])=O)C=C1 RYYNDHCHTCVQJH-KWWJGWKXSA-N 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 6
- 238000003752 polymerase chain reaction Methods 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 238000012300 Sequence Analysis Methods 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 238000009396 hybridization Methods 0.000 claims description 2
- 238000000734 protein sequencing Methods 0.000 claims description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 2
- 238000003757 reverse transcription PCR Methods 0.000 claims description 2
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims 7
- 108010019421 Janus Kinase 3 Proteins 0.000 description 80
- 108010024121 Janus Kinases Proteins 0.000 description 37
- 102000015617 Janus Kinases Human genes 0.000 description 22
- 239000000523 sample Substances 0.000 description 18
- 102200007971 rs5972599 Human genes 0.000 description 17
- 108010002350 Interleukin-2 Proteins 0.000 description 15
- 102000000588 Interleukin-2 Human genes 0.000 description 15
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 14
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 210000000822 natural killer cell Anatomy 0.000 description 12
- 102220143455 rs768320190 Human genes 0.000 description 10
- 238000007480 sanger sequencing Methods 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 9
- 238000006366 phosphorylation reaction Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 7
- 230000005754 cellular signaling Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 206010025323 Lymphomas Diseases 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000010200 validation analysis Methods 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 4
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 102200087780 rs77375493 Human genes 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 238000000719 MTS assay Methods 0.000 description 3
- 231100000070 MTS assay Toxicity 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010040476 FITC-annexin A5 Proteins 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000004012 Tofacitinib Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 108700025316 aldesleukin Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000719 anti-leukaemic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000035578 autophosphorylation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940087463 proleukin Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960001350 tofacitinib Drugs 0.000 description 2
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108091034120 Epstein–Barr virus-encoded small RNA Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 208000005599 HTLV-I Infections Diseases 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
- 101000802734 Homo sapiens eIF5-mimic protein 2 Proteins 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 102000007078 STAT Transcription Factors Human genes 0.000 description 1
- 108010072819 STAT Transcription Factors Proteins 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000000887 Transcription factor STAT Human genes 0.000 description 1
- 108050007918 Transcription factor STAT Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000001908 autoinhibitory effect Effects 0.000 description 1
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 230000037011 constitutive activity Effects 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 102100035859 eIF5-mimic protein 2 Human genes 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000004784 molecular pathogenesis Effects 0.000 description 1
- 238000011395 multi-agent chemotherapy Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- SYIKUFDOYJFGBQ-YLAFAASESA-N tofacitinib citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 SYIKUFDOYJFGBQ-YLAFAASESA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000007482 whole exome sequencing Methods 0.000 description 1
- 229940039916 xeljanz Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Definitions
- the present invention relates to cancer therapy and/or diagnosis.
- it relates to Natural-Killer/T-Cell Lymphoma (NKTCL) therapy and/or diagnosis.
- NTCL Natural-Killer/T-Cell Lymphoma
- NK-cell lymphoma is a type of non-Hodgkin lymphoma (NHL). Most NHLs (90%) are of B-cell origin. NK-cell lymphomas do not arise from B-cells. However, controversy still exists over the normal cell from which NK-cell lymphomas arise. In particular, whether NK-cell lymphoma represents the presence of a true NK cell or merely the presence of a T cell with abnormal cell markers is under debate. In the absence of unequivocal proof of the exact lineage of NK-cell lymphoma, many investigators prefer to use the term NK/T-cell lymphoma (NKTCL) when classifying this condition.
- NHLs non-Hodgkin lymphoma
- Natural-killer T-cell lymphoma is particularly prevalent in Asian countries and some parts of Latin America. It accounts for up to half of all mature T cell lymphoma cases in Asia (1). However, compared to the more common B cell lymphomas, very little is known about its molecular characteristics and pathogenesis. There has been little progress in basic science and clinical research in this subtype of lymphoma, which continues to constitute a major challenge in managing these patients as there is currently no accepted standard first-line treatment for NKTCL. Despite multi-agent chemotherapy and involved-field radiotherapy, the 5-year overall survival is approximately 9% for non-nasal NKTCL and 42% for nasal NKTCL (2, 3).
- NKTCLs Compared to B cell lymphomas which are relatively more common, very little is known about the molecular characteristics and pathogenesis of NKTCLs. This may be in part due to relative rarity in the West and difficulty in obtaining adequate biopsy. Treatment of NKTCLs with conventional chemotherapy has thus far yielded poor results and the outcome is almost always fatal for patients with stage III or IV disease.
- the present invention relates to cancer therapy and/or diagnosis, in particular Natural-Killer/T-Cell Lymphoma (NKTCL) therapy and/or diagnosis.
- NTCL Natural-Killer/T-Cell Lymphoma
- the present invention relates to a method for predicting Natural Killer T-Cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject, comprising testing for the genotype of said subject for at least one JAK gene, wherein the presence of a mutant JAK gene indicates that a subject is at risk of developing and/or has NKTCL.
- NKTCL Natural Killer T-Cell Lymphoma
- the invention also relates to a method for predicting Natural Killer T-Cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject, comprising testing for whether said subject expresses a wildtype or mutant JAK protein, wherein expression of a mutant JAK protein indicates that the subject is at risk of developing and/or has NKTCL.
- NKTCL Natural Killer T-Cell Lymphoma
- the invention relates to a method for screening for an agent capable of treating NKTCL, comprising:
- the invention relates to a method for screening for an agent capable of reducing the activity of at least one of JAK protein, comprising:
- an NKTCL animal model comprising at least one mutant JAK gene.
- the invention relates to a method of treating Natural Killer T-Cell Lymphoma (NKTCL) comprising administering a JAK inhibitor to a subject.
- NTCL Natural Killer T-Cell Lymphoma
- the invention also includes use of a JAK inhibitor in the preparation of a medicament for the treatment of Natural Killer T-Cell Lymphoma (NKTCL).
- NKTCL Natural Killer T-Cell Lymphoma
- the invention further includes a JAK inhibitor for use in treating Natural Killer T-Cell Lymphoma (NKTCL).
- NKTCL Natural Killer T-Cell Lymphoma
- FIG. 1 shows High-resolution melt (HRM) and Sanger sequencing data leading to the identification of JAK3 A572V and A573V mutations in NKTCL samples.
- FIG. 1 . ( a ) shows the location of the A572V and A573V mutation on the JH2 pseudokinase domain of the JAK3 gene.
- High-resolution melt (HRM) and Sanger sequencing data used to validate JAK3 mutations are shown in FIG. 1( b ) through ( h ).
- FIG. 1( c ) shows HRM difference plots (in replicates) normalized to the wild-type sample for three genotypes: wild-type JAK3, heterozygous JAK3 (c.1715C>T, p.Ala572Val) and homozygous JAK3 (c.1715C>T, p.Ala572Val).
- FIG. 1( d ) shows representative HRM difference curves of an Formalin-Fixed Paraffin-Embedded (FFPE) NKTCL sample which was sequenced and confirmed as heterozygous JAK3 (c.1718C>T, p.Ala573Val) mutation.
- FFPE Formalin-Fixed Paraffin-Embedded
- FIG. 1 ( e ) Representative sequencing chromatograms are also shown in FIG. 1 ( e ) for the JAK3 wild-type allele, FIG. 1( f ) for the A572V heterozygous mutant, FIG. 1( g ) for the A573V heterozygous mutant, and FIG. 1( h ) for the A572V homozygous mutant.
- FIG. 2 shows data demonstrating the effect of IL-2 on JAK3 and STAT5 phosphorylation and CP-690,550 treatment on NKTCL cell lines.
- FIG. 2 ( a ) shows immunoblotting results for NK-S1 (JAK-mutant) and KHYG-1 (wild-type) cells which were cultured with or without recombinant human IL-2 (200 IU/ml), harvested at 48 h, and assayed for JAK3 and STAT5 phosphorylation by immunoblotting.
- NK-S1, KHYG-1 and K562 (control) cell lines were treated with the pan-JAK inhibitor CP-690,550 and the results of evaluation are shown in FIG. 2( b ) through 2 ( d ).
- FIG. 2( b ) shows STAT5 phosphorylation in the samples evaluated by immunoblotting at 48 h.
- FIG. 2( c ) shows cell viability analyzed by MTS assay at 72 h.
- FIG. 2( d ) shows drug-induced apoptosis at 72 h evaluated by Annexin V-FITC staining and analyzed by flow cytometry. Experiments were repeated at least three times. Results in c and d represent the average of triplicates ⁇ s.e.m. * Indicates p ⁇ 0.05 by paired Student's t-test.
- FIG. 3 provides data showing Cytokine independent growth of the mutant NKTCL cell line, NK-S1.
- NK-S1 JAK3 mutant
- KHYG-1 JAK3 wild-type
- FIG. 3( a ) Cell viability data is shown in FIG. 3( a ) for NK-S1 and in FIG. 3( b ) for KHYG-1.
- Cell viability was monitored daily with MTS assay for seven days and cell growth was expressed as absorbance at 490 nm minus the reference at 650 nm. Results in a and b represent the average of triplicates ⁇ s.d.
- FIG. 4 shows data demonstrating that JAK3 A572V mutation causes constitutive JAK3 activity and IL-2 independent proliferation of NKTCL cells.
- FIG. 4A shows data for NK-S1 cells which were treated with 100 nM JAK3 siRNA (si-JAK3) or control siRNA (si-Ctrl) for 24 h prior and subjected to proliferation assays up to 72 h (Right panel). In parallel, these cells were harvested and protein extracts were subjected to Western blotting with antibodies against phosphorylated JAK3 (pJAK3), phosphorylated. STAT5 (pSTAT5), JAK3, STAT5, or ⁇ -actin as a normalization control.
- FIG. 4A shows data for NK-S1 cells which were treated with 100 nM JAK3 siRNA (si-JAK3) or control siRNA (si-Ctrl) for 24 h prior and subjected to proliferation assays up to 72 h (Right panel). In parallel, these cells were
- FIG. 4B shows data for KHYG-1 cells which were transiently transfected with wild-type JAK3 (JAK3 WT) or mutated JAK3 expression vectors (i.e. JAK3 A572V).
- JAK3 WT wild-type JAK3
- JAK3 A572V mutated JAK3 expression vectors
- the relative pJAK3, pSTAT5, JAK3 and STAT5 levels in these cells were detected by Western blotting (upper panel), and proliferation assays using these cells were performed for 48 h with or without IL-2 (lower panel). All results are expressed as mean SEM of three independent experiments. *, p ⁇ 0.05 compared with Vehicle control (Vehicle).
- the term “inhibitor” refers to any substance which is able to reduce the activity of a protein, for example a JAK inhibitor is able to reduce the activity of a JAK protein.
- a JAK3 inhibitor is able to reduce the activity of a JAK3 protein. Reducing the activity of a protein may be direct or indirect—for example, by interfering with the expression of the protein or the mechanism by which the protein functions in a biological context.
- the JAK3 kinase may require binding of a molecule of ATP to an ATP-binding site, so by specifically binding to and blocking the ATP-binding site, the activity of the JAK3 kinase is reduced.
- the activity of the JAK protein may also require the activity of another protein, such as a cytokine receptor, so interference with the activity of this protein may also reduce the activity of the JAK protein.
- cytokine receptor a protein that promotes the expression of the JAK protein.
- fewer JAK3 kinase proteins may be expressed by interfering with gene expression at the relevant nucleic acid domain, such as the translation of the corresponding mRNA.
- NKTCL refers to NK/T cell lymphoma in accordance with WHO classification (6).
- the terms “Natural Killer T-Cell Lymphoma,” NKTCL and “NK/T-cell lymphoma” are used interchangeably to refer to a type of non-Hodgkin lymphoma (NHL) that is not of B-cell origin.
- NKTCL has the classic morphology of tumor necrosis, angiocentricity as well as the appropriate immunophenotype, in particular, presence of CD56, cytoplasmic CD3 as well as near universal presence of EBER.
- NK/T cell lymphoma differs from Adult T cell Leukemia/Lymphoma, which is a disease of the T cell lineage and associated with HTLV-I infection.
- treating includes alleviating, preventing and/or eliminating one or more symptoms associated with a disease, for example Natural killer/T-cell Lymphoma (NKTCL)
- NKTCL Natural killer/T-cell Lymphoma
- the present invention relates to cancer therapy and/or diagnosis, in particular Natural-Killer/T-Cell Lymphoma (NKTCL) therapy and/or diagnosis.
- NTCL Natural-Killer/T-Cell Lymphoma
- a method for predicting Natural Killer T-Cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject comprising testing for the genotype of said subject for at least one JAK gene wherein the presence of a mutant JAK gene indicates that a subject is at risk of developing and/or has NKTCL.
- the presence of either a heterozygous or homozygous mutant JAK gene indicates that the subject is at risk of developing and/or has NKTCL.
- JAK genes may be tested.
- the JAK gene tested may be selected from the group consisting of JAK1, JAK2, JAK3 and TYK2.
- the JAK3 and/or JAK1 genes may be tested.
- SEQ ID NO: 1 indicates a wildtype JAK3 gene.
- the presence of a mutant JAK3 gene comprising a substitution of C with T at nucleotide 15792 and/or a substitution of C with T at nucleotide 15795 of SEQ ID NO: 1 indicates that a subject is at risk of developing and/or has NKTCL.
- SEQ ID NO: 3 indicates a wildtype JAK1 gene.
- the presence of a mutant JAK1 gene comprises a substitution of T with G at nucleotide 124823 of SEQ ID NO: 3 indicates that a subject is susceptible and/or has NKTCL.
- the presence of both mutant JAK1 and JAK3 genes also indicate that a subject is at risk of developing and/or has NKTCL.
- the method may be performed on an isolated cell sample from the subject.
- the isolated cell sample may be from a blood and/or tumour sample. Accordingly, the method may further comprise providing an isolated cell sample from the subject for testing.
- the method may further comprise isolating nucleic acid molecules from the subject, blood sample and/or isolated cell sample for said testing.
- the isolated nucleic acid molecules may comprise genomic DNA or mRNA.
- the testing may be performed on genomic DNA, mRNA and/or cDNA.
- testing may be by sequence analysis, restriction fragment length polymorphism analysis, hybridization, polymerase chain reaction (PCR) and/or reverse transcription PCR.
- PCR polymerase chain reaction
- techniques such as Sanger sequencing and High resolution melt may be used for testing.
- NKTCL Natural Killer T-Cell Lymphoma
- JAK protein tested may be selected from the group consisting of JAK1, JAK2, JAK3 and TYK2.
- the JAK3 and/or JAK1 proteins may be tested.
- SEQ ID NO: 2 indicates a wildtype JAK3 protein.
- the presence of a mutant JAK3 gene comprising a substitution of A with V at amino acid 572 and/or a substitution of A with V at amino acid 573 of SEQ ID NO: 2 indicates that a subject is at risk of developing and/or has NKTCL.
- SEQ ID NO: 4 indicates a wildtype JAK1 protein.
- the presence of a mutant JAK1 protein comprising a substitution of Y with D at amino acid 652 of SEQ ID NO: 4 indicates a subject at risk of developing and/or has NKTCL.
- the presence of both mutant JAK3 and JAK1 proteins also indicate a subject at risk of developing and/or has NKTCL.
- the method may be performed on an isolated blood and/or cell sample from the subject.
- the isolated cell sample may be from a tumour.
- the method may further comprise providing an isolated blood and/or cell sample from the subject for testing.
- the method may further comprise isolating proteins molecules from the subject, blood sample and/or isolated cell sample for said testing.
- Any suitable method may be used to detect whether the relevant wildtype and/or mutant JAK protein is expressed.
- testing may be by protein sequencing and/or antibody detection.
- Enzyme-linked immunosorbent assay ELISA
- ELISA Enzyme-linked immunosorbent assay
- a method for screening for an agent capable of treating NKTCL comprising:
- a method for screening for an agent capable of reducing the activity of at least one JAK protein comprising:
- the NKTCL cell line may carry any one or a combination of any of mutant JAK1, JAK2, JAK3 or TYK2 genes.
- the NKTCL cell line may carry a mutant JAK3 gene and/or a mutant JAK1 gene.
- the mammalian NKTCL cell line may carry at least one of the following mutations:
- the invention also relates to an NKTCL animal model comprising at least one mutant JAK gene.
- the NKTCL animal model may comprise at least one mutation selected from the group consisting of mutant JAK1, JAK2, JAK3 and TYK2 genes.
- the NKTCL animal model comprises a mutant JAK3 gene and/or a mutant JAK1 gene. More in particular, the NKTCL animal model comprises at least one of the following mutations:
- the NKTCL animal model may also be useful for screening candidate agents capable of treating NKTCL.
- a method of treating Natural Killer T-Cell Lymphoma comprising administering at least one JAK inhibitor to a subject.
- Any suitable JAK inhibitor may be used.
- the JAK inhibitor may able to reduce the activity of JAK3 protein.
- the JAK inhibitor may inhibit at least one of JAK1, JAK2, JAK3 and/or TYK2. Accordingly, the inhibitor may be a pan-JAK inhibitor.
- the JAK inhibitor may inhibit JAK3 and/or JAK1. More in particular, the JAK inhibitor may inhibit JAK3 or the JAK inhibitor may also inhibit JAK1.
- the JAK inhibitor may comprise 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile (also known as CP-690,550).
- the JAK inhibitor may comprise (E)-2-cyano-3-(4-nitrophenyl)-N-((R)-1-phenylethyl)acrylamide (also known as WP-1034).
- the subject to whom the JAK inhibitor is administered may comprise a mammal.
- the subject may comprise a human.
- the subject may carry a homozygous or heterozygous mutation in at least one of the JAK genes/JAK proteins.
- the subject may carry a homozygous or heterozygous mutation in JAK1/JAK1, JAK2/JAK2, JAK3/JAK3 and/or TYK2/TYK2.
- the subject may carry a homozygous or heterozygous mutation in JAK1/JAK1 and/or JAK3/JAK3.
- the subject may have at least one mutation selected from the group consisting of JAK3-A572V, JAK3-A573V and JAK1-Y652D.
- the subject may also comprise a homozygous wildtype phenotype.
- the subject may have increased expression of any one of the JAK genes, its transcriptional and/or translational products (proteins), whether it carries a homozygous wildtype, heterozygous or homozygous mutant gene.
- CP-690,550 is a JAK inhibitor. It is known as Tofacitinib, Tasocitinib, or by the trade name XELJANZ. Its chemical name is 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile and its structural formula is:
- WP-1034 has been described as having proapoptotic and antileukemic activity in Acute Myeloid Leukemia (Faderl et al., Anticancer Research 25: 1841-1850 (2005)) (8). It is a member of the tyrphostin family of tyrosine kinase inhibitors, which has been predominantly studied as an inhibitor of the Jak-Stat pathway. Its chemical structure and name are as follows:
- NKTCL Natural-killer/T-cell lymphoma
- JAK3 Janus kinase 3
- HRM High Resolution Melt
- NKTCL cell line harbouring JAK3 A572V mutation showed IL-2 independent growth and constitutive JAK3 and STAT5 phosphorylation suggesting its oncogenic role. Functional characterization of the JAK3 mutations support its involvement in cytokine-independent JAK/STAT constitutive activation leading to increased cell growth. These mutations may play a significant role in the pathogenesis of NKTCL. Moreover, treatment of both JAK3-mutant and wild-type NKTCL cell lines with a novel pan-JAK inhibitor, CP-690,550, resulted in dose dependent reduction of phosphorylated STAT5, reduced cell viability and increased apoptosis.
- a novel pan-JAK inhibitor CP-690,550
- CP-690,550 is a pan-JAK inhibitor, having an inhibitory effect on not just JAK3 but also JAK1. This may be important because in their function within the JAK-STAT signalling pathway system, JAK1 and JAK3 cross-talk and there may be some compensatory upregulation of one in response to inhibition of the other. For example, if JAK3 is inhibited, JAK1 may be upregulated so as to compensate for the reduced activity of JAK3, and this may preserve JAK-STAT signalling. The reverse may also apply. To take the example further, treatment of NKTCL using a pan-JAK inhibitor that is able to reduce the activity of not just JAK1 but JAK3 as well may be especially effective at inhibiting JAK-STAT signalling.
- NKTCL Matched fresh-frozen tissue and peripheral blood samples were obtained from four consented patients with NKTCL.
- the inventors further identified paraffin-embedded tissue blocks from 61 patients with NKTCL for validation.
- the diagnosis of NKTCL was made according to the 2008 World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues (6). All samples were centrally reviewed by Singhealth hematopathologists. This study was approved by the SingHealth Centralized Institutional Review Board, Singapore.
- WHO World Health Organization
- DNA of frozen tissue and paired blood samples was isolated using a DNeasy Blood and Tissue Mini Kit (Qiagen) and a QIAmp DNA Blood Midi Kit (Qiagen), respectively, according to manufacturer's instruction.
- FFPE Formalin-Fixed Paraffin-Embedded
- Genomic DNA of extracted from each sample was whole genome amplified with REPLI-g WGA Midi Kit (Qiagen).
- the coding exonic sequences of JAK1, JAK2, JAK3 and Tyk2 were sequenced by Sanger sequencing to detect mutations. Somatic origin of the mutations were confirmed when the mutations were only detected in the tumor but not in the paired blood sample.
- High-resolution melt (HRM) and Sanger sequencing were used to confirm the JAK1 and JAK3 mutations and validate their prevalence in the NKTCL patient population. Combining both methods will greatly improve the precision of mutation detection in FFPE samples.
- the JAK2 V617F mutation was also sequenced with both methods.
- the sequences of primer sets used for validation are listed in Table 2 (see below) and included in the accompanying sequence listings under the corresponding identifiers.
- HRM Curve Analysis was used to discern the presence of the point mutations.
- SsoFastTM EvaGreen Supermix® (Bio Rad, Cat. No. 172-5200) was used for amplification of target DNA fragments encompassing the relevant mutations from genomic DNA samples.
- HRM primers were used at a final concentration of 600 nM and reactions were performed with BioRad CFX96 Real time PCR Detection System in replicates. The cycling and melting conditions were as follows: one cycle of 98° C. for 2 min; 39 cycles of 98° C. for 5 sec, 58° C. for 10 sec; one cycle of 95° C. for 30 min and a melt from 72° C. to 95° C. rising at 0.2° C./sec.
- the HRM curves were analyzed with the Biorad Precision Melt AnalysisTM software. HRM difference curves deviating from the wild-type curve were considered to be harbouring a mutation.
- PCR was performed with Invitrogen Platinum Taq Polymerase (Cat. No. 10966-083) and cycled at 95° C. for 10 min; 39 cycles of 95° C. for 30 sec; 60° C. for 30 sec, 72° C. for 1 minute and a final extension of 72° C. for 10 min.
- Sequencing PCR was performed with ABI BigDye Terminator v3.1 (Cat. No. 4337457) and cycled at 96° C. for 1 min; 29 cycles of 96° C. for 10 sec; 50° C. for 5 sec & 60° C. for 4 min. The resulting products were run on ABI 3730 DNA Analyzer.
- NK-S1 is a cell line established from a previously described NKTCL xenograft (7).
- the xenograft was derived from metastatic tumor of the testis from the same patient found to have both JAK1 (Y652D) and JAK3 (A572V) mutations.
- NK-S1 was cultured for more than 60 passages in DMEM medium supplemented with antibiotics, heat-inactivated FBS (10%) and equine serum (ES) (10%).
- Phenotypic analysis showed surface CD3 ⁇ CD56 + , and Granzyme B + by intracellular staining.
- NK-S1 NKTCL cell line was sequenced and confirmed to carry homozygous mutation for JAK3 A572V, as well as a mutation on JAK1 codon 652.
- KHYG-1 is an IL-2 dependent aggressive NK leukemia cell line obtained from the Japanese Collection of Research Bioresources, and it was cultured in RPMI medium supplemented with antibiotics, heat-inactivated FBS (10%), ES (10%) and 200 IU/ml of recombinant human IL-2 (Proleukin, Novartis) 7 .
- KHYG-1 was sequenced and found to be wild-type for JAK3 codon 572 and 573, and JAK1 codon 652 and 658.
- K562 (CCL-234, ATCC) is a chronic myeloid leukemia (CML) cell line positive for the BCR-ABL fusion gene.
- NKTCL cell lines to CP-690,550 (Selleck Chemical, Cat. No. S5001)
- CP-690,550 a pan-JAK inhibitor
- the viability was evaluated by MTS assay using a CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay Kit (Promega), absorbance was read at both 490 nm and 650 nm (as reference).
- the extent of drug-induced apoptosis was evaluated by Annexin V-FITC (BD Biosciences) staining. Acquisition of the data was performed on a FACSCalibur flow cytometer (BD Biosciences).
- Cells were harvested at indicated time intervals after incubation with or without recombinant human IL-2 (Proleukin, Novartis), or in the presence or absence of CP-690,550. Cells were washed with ice-cold phosphate buffer saline (PBS) and lysed in 50 ⁇ l of ice-cold RIPA buffer [25 mM Tris-HCL, pH 7.6, 150 mM NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 1 ⁇ Phosphatase Inhibitor (Cat. No. 78420, Thermo Fisher Scientific), 1 ⁇ Protease Inhibitor (Cat. No.
- JAK1 Y652D mutant No additional JAK1 Y652D mutant was found.
- JAK2 V617F p.Val617Phe or c.1849G>T
- myelodysplastic syndrome and acute myeloid leukemia.
- IL-2 is an essential cytokine required for the proliferation and activation of NK cells (4). JAK1 and JAK3 mediate IL-2 receptor signaling through phosphorylation of STAT transcription factors (5). In line with the functional importance of the activating JAK3 mutations identified, we tested if JAK3 mutations could confer IL-2 independent growth to the NKTCL cell line (NK-S1) that harbors a homozygous JAK3 A572V mutation. JAK-mutant (NK-S1) cells showed IL-2 independent growth ( FIG. 3 ) and constitutive phosphorylation of both JAK3 and STAT5 ( FIG. 2 a ). In contrast, JAK3-wild type KHYG-1 cells were clearly IL-2 dependent ( FIGS.
- NK-S1 cells treated with JAK3 siRNAs exhibited a significant reduction in cell proliferation and also decreased autophosphorylation of JAK3 and STAT5, compared with cells treated with control siRNAs ( FIG. 4A ).
- KHYG-1 cells transiently over-expressing a mutated JAK3 (JAK3 A572V ) cDNA demonstrated IL-2 independent proliferation and autophosphorylation of JAK3 and STAT5 ( FIG. 4B ).
- JAK mutations confers cytokine independent growth in a NKTCL cell line established from xenograft derived from patient sample harboring both JAK3 A572V and JAK1 Y652D mutation.
- NK-S1 showed IL-2 independent growth ( FIG. 3 ), constitutive JAK3 and STAT5 phosphorylation ( FIG. 2 a ) in contrast to the wild-type KHYG-1, which was tested not to carry JAK1 and JAK3 mutations identified ( FIG. 2 a ).
- CP-690,550 a pan-JAK inhibitor
- a pan-JAK inhibitor to suppress the JAK-STAT pathway.
- activated JAK proteins directly phosphorylate STAT proteins
- the JAK-mutated cell line (NK-S1) and the wild-type NKTCL cell line (KHYG-1) were treated with increasing concentrations of CP-690,550 and analyzed the pSTAT5 by immunoblotting ( FIG. 2 b ). Both the NK-S1 and KHYG-1 cell lines showed a dose-dependent reduction of pSTAT5 ( FIG. 2 a ) and reduced cell viability ( FIG. 2 b ) upon treatment with the inhibitor.
- CP-690,550 did not inhibit pSTAT5 in the control K562 cell lines since its STAT5 phosphorylation is independent of activated JAK3 ( FIG. 2 b ).
- the reduced viability of NK-S1 correlated with increased apoptosis as shown by Annexin V staining ( FIG. 2 c ).
- JAK3 A572 and A573V and JAK1 Y652D mutations have been identified in NKTCL patients, and the prevalence of JAK3 mutations was validated to be 35.4%.
- a mutant NKTCL cell line harboring JAK3 A572V mutation showed IL-2 independent growth and constitutive JAK3 and STAT5 phosphorylation suggesting an oncogenic role for mutations in the corresponding nucleic acid domain.
- pan-Jak inhibitor could be a new therapeutic agent for NKTCL patients.
- CP-690,550 a pan-JAK-inhibitor, was shown to reduce cell viability and cause apoptosis in both JAK3 wild-type (KHYG-1) and mutant (NK-S1) cell lines.
- KHYG-1 is an IL-2 dependent NKTCL cell line, thus its sensitivity to pan-JAK inhibitor.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
Abstract
Natural-Killer T-Cell Lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy. The invention relates to a method for predicting Natural Killer T-cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject comprising testing for JAK mutations. The invention also relates to a method of screening for candidate agents capable of treating NKTCL using a cell line comprising at least one JAK mutation. The invention includes an NKTCL animal model comprising at least one JAK mutation. The invention also includes JAK inhibitors for treating NKTCL.
Description
- The present invention relates to cancer therapy and/or diagnosis. In particular, it relates to Natural-Killer/T-Cell Lymphoma (NKTCL) therapy and/or diagnosis.
- Natural killer (NK)-cell lymphoma is a type of non-Hodgkin lymphoma (NHL). Most NHLs (90%) are of B-cell origin. NK-cell lymphomas do not arise from B-cells. However, controversy still exists over the normal cell from which NK-cell lymphomas arise. In particular, whether NK-cell lymphoma represents the presence of a true NK cell or merely the presence of a T cell with abnormal cell markers is under debate. In the absence of unequivocal proof of the exact lineage of NK-cell lymphoma, many investigators prefer to use the term NK/T-cell lymphoma (NKTCL) when classifying this condition.
- Natural-killer T-cell lymphoma (NKTCL) is particularly prevalent in Asian countries and some parts of Latin America. It accounts for up to half of all mature T cell lymphoma cases in Asia (1). However, compared to the more common B cell lymphomas, very little is known about its molecular characteristics and pathogenesis. There has been little progress in basic science and clinical research in this subtype of lymphoma, which continues to constitute a major challenge in managing these patients as there is currently no accepted standard first-line treatment for NKTCL. Despite multi-agent chemotherapy and involved-field radiotherapy, the 5-year overall survival is approximately 9% for non-nasal NKTCL and 42% for nasal NKTCL (2, 3).
- Compared to B cell lymphomas which are relatively more common, very little is known about the molecular characteristics and pathogenesis of NKTCLs. This may be in part due to relative rarity in the West and difficulty in obtaining adequate biopsy. Treatment of NKTCLs with conventional chemotherapy has thus far yielded poor results and the outcome is almost always fatal for patients with stage III or IV disease.
- It is desirable to identify novel genetic aberrations and potential treatment targets in NKTCL, as well as potential therapeutic agents for NKTCL.
- The present invention relates to cancer therapy and/or diagnosis, in particular Natural-Killer/T-Cell Lymphoma (NKTCL) therapy and/or diagnosis.
- According to a first aspect, the present invention relates to a method for predicting Natural Killer T-Cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject, comprising testing for the genotype of said subject for at least one JAK gene, wherein the presence of a mutant JAK gene indicates that a subject is at risk of developing and/or has NKTCL.
- The invention also relates to a method for predicting Natural Killer T-Cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject, comprising testing for whether said subject expresses a wildtype or mutant JAK protein, wherein expression of a mutant JAK protein indicates that the subject is at risk of developing and/or has NKTCL.
- According to a second aspect, the invention relates to a method for screening for an agent capable of treating NKTCL, comprising:
-
- (i) providing a NKTCL cell line comprising at least one mutant JAK gene;
- (ii) contacting the NKTCL cell line with the agent; and
- (iii) determining the effect of the agent on the mammalian NKTCL cell line;
- wherein the ability of the agent to reduce the viability, growth and/or multiplication and/or increase apoptosis of the NKTCL cell line is indicative of the ability of the agent to treat NKTCL.
- According to a third aspect, the invention relates to a method for screening for an agent capable of reducing the activity of at least one of JAK protein, comprising:
-
- (i) providing a NKTCL cell line carrying a mutant JAK gene;
- (ii) contacting the NKTCL cell line with the agent; and
- (iii) determining the effect of the agent on the NKTCL cell line;
- wherein the ability of the agent to reduce the viability, growth and/or multiplication and/or increase apoptosis of is indicative of the ability of the candidate agent to reduce the activity of at least one JAK protein.
- According to a fourth aspect, there is provided an NKTCL animal model comprising at least one mutant JAK gene.
- According to a fifth aspect, the invention relates to a method of treating Natural Killer T-Cell Lymphoma (NKTCL) comprising administering a JAK inhibitor to a subject.
- The invention also includes use of a JAK inhibitor in the preparation of a medicament for the treatment of Natural Killer T-Cell Lymphoma (NKTCL).
- The invention further includes a JAK inhibitor for use in treating Natural Killer T-Cell Lymphoma (NKTCL).
-
FIG. 1 shows High-resolution melt (HRM) and Sanger sequencing data leading to the identification of JAK3 A572V and A573V mutations in NKTCL samples.FIG. 1 . (a) shows the location of the A572V and A573V mutation on the JH2 pseudokinase domain of the JAK3 gene. High-resolution melt (HRM) and Sanger sequencing data used to validate JAK3 mutations are shown inFIG. 1( b) through (h). In particular:FIG. 1( b) shows the percentage of the JAK3 A572V and A573V mutations in the pie chart (n=65).FIG. 1( c) shows HRM difference plots (in replicates) normalized to the wild-type sample for three genotypes: wild-type JAK3, heterozygous JAK3 (c.1715C>T, p.Ala572Val) and homozygous JAK3 (c.1715C>T, p.Ala572Val).FIG. 1( d) shows representative HRM difference curves of an Formalin-Fixed Paraffin-Embedded (FFPE) NKTCL sample which was sequenced and confirmed as heterozygous JAK3 (c.1718C>T, p.Ala573Val) mutation. Notably, HRM difference plots for sample with either JAK3 A572V or A573V mutation were similar due to the same C>T conversion. Representative sequencing chromatograms are also shown inFIG. 1 (e) for the JAK3 wild-type allele,FIG. 1( f) for the A572V heterozygous mutant,FIG. 1( g) for the A573V heterozygous mutant, andFIG. 1( h) for the A572V homozygous mutant. -
FIG. 2 shows data demonstrating the effect of IL-2 on JAK3 and STAT5 phosphorylation and CP-690,550 treatment on NKTCL cell lines.FIG. 2 (a) shows immunoblotting results for NK-S1 (JAK-mutant) and KHYG-1 (wild-type) cells which were cultured with or without recombinant human IL-2 (200 IU/ml), harvested at 48 h, and assayed for JAK3 and STAT5 phosphorylation by immunoblotting. NK-S1, KHYG-1 and K562 (control) cell lines were treated with the pan-JAK inhibitor CP-690,550 and the results of evaluation are shown inFIG. 2( b) through 2(d).FIG. 2( b) shows STAT5 phosphorylation in the samples evaluated by immunoblotting at 48 h.FIG. 2( c) shows cell viability analyzed by MTS assay at 72 h.FIG. 2( d) shows drug-induced apoptosis at 72 h evaluated by Annexin V-FITC staining and analyzed by flow cytometry. Experiments were repeated at least three times. Results in c and d represent the average of triplicates±s.e.m. * Indicates p<0.05 by paired Student's t-test. -
FIG. 3 provides data showing Cytokine independent growth of the mutant NKTCL cell line, NK-S1. In particular, NK-S1 (JAK3 mutant) and KHYG-1 (JAK3 wild-type) were cultured with or without recombinant human IL-2 (0 to 200 IU/ml). Cell viability data is shown inFIG. 3( a) for NK-S1 and inFIG. 3( b) for KHYG-1. Cell viability was monitored daily with MTS assay for seven days and cell growth was expressed as absorbance at 490 nm minus the reference at 650 nm. Results in a and b represent the average of triplicates±s.d. -
FIG. 4 shows data demonstrating that JAK3 A572V mutation causes constitutive JAK3 activity and IL-2 independent proliferation of NKTCL cells.FIG. 4A shows data for NK-S1 cells which were treated with 100 nM JAK3 siRNA (si-JAK3) or control siRNA (si-Ctrl) for 24 h prior and subjected to proliferation assays up to 72 h (Right panel). In parallel, these cells were harvested and protein extracts were subjected to Western blotting with antibodies against phosphorylated JAK3 (pJAK3), phosphorylated. STAT5 (pSTAT5), JAK3, STAT5, or β-actin as a normalization control.FIG. 4B shows data for KHYG-1 cells which were transiently transfected with wild-type JAK3 (JAK3 WT) or mutated JAK3 expression vectors (i.e. JAK3 A572V). The relative pJAK3, pSTAT5, JAK3 and STAT5 levels in these cells were detected by Western blotting (upper panel), and proliferation assays using these cells were performed for 48 h with or without IL-2 (lower panel). All results are expressed as mean SEM of three independent experiments. *, p<0.05 compared with Vehicle control (Vehicle). - As used in the present specification, the term “inhibitor” refers to any substance which is able to reduce the activity of a protein, for example a JAK inhibitor is able to reduce the activity of a JAK protein. In particular, a JAK3 inhibitor is able to reduce the activity of a JAK3 protein. Reducing the activity of a protein may be direct or indirect—for example, by interfering with the expression of the protein or the mechanism by which the protein functions in a biological context. For example, the JAK3 kinase may require binding of a molecule of ATP to an ATP-binding site, so by specifically binding to and blocking the ATP-binding site, the activity of the JAK3 kinase is reduced. The activity of the JAK protein may also require the activity of another protein, such as a cytokine receptor, so interference with the activity of this protein may also reduce the activity of the JAK protein. Alternatively, fewer JAK3 kinase proteins may be expressed by interfering with gene expression at the relevant nucleic acid domain, such as the translation of the corresponding mRNA.
- NKTCL refers to NK/T cell lymphoma in accordance with WHO classification (6). The terms “Natural Killer T-Cell Lymphoma,” NKTCL and “NK/T-cell lymphoma” are used interchangeably to refer to a type of non-Hodgkin lymphoma (NHL) that is not of B-cell origin. NKTCL has the classic morphology of tumor necrosis, angiocentricity as well as the appropriate immunophenotype, in particular, presence of CD56, cytoplasmic CD3 as well as near universal presence of EBER. NK/T cell lymphoma differs from Adult T cell Leukemia/Lymphoma, which is a disease of the T cell lineage and associated with HTLV-I infection.
- The term “treating” includes alleviating, preventing and/or eliminating one or more symptoms associated with a disease, for example Natural killer/T-cell Lymphoma (NKTCL)
- The present invention relates to cancer therapy and/or diagnosis, in particular Natural-Killer/T-Cell Lymphoma (NKTCL) therapy and/or diagnosis.
- According to a first aspect, there is provided a method for predicting Natural Killer T-Cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject, comprising testing for the genotype of said subject for at least one JAK gene wherein the presence of a mutant JAK gene indicates that a subject is at risk of developing and/or has NKTCL. The presence of either a heterozygous or homozygous mutant JAK gene indicates that the subject is at risk of developing and/or has NKTCL.
- Any one or a combination of any of the JAK genes may be tested. The JAK gene tested may be selected from the group consisting of JAK1, JAK2, JAK3 and TYK2. For example, the JAK3 and/or JAK1 genes may be tested. In general, SEQ ID NO: 1 indicates a wildtype JAK3 gene. In one example, the presence of a mutant JAK3 gene comprising a substitution of C with T at nucleotide 15792 and/or a substitution of C with T at nucleotide 15795 of SEQ ID NO: 1 indicates that a subject is at risk of developing and/or has NKTCL.
- In general, SEQ ID NO: 3 indicates a wildtype JAK1 gene. In another example, the presence of a mutant JAK1 gene comprises a substitution of T with G at nucleotide 124823 of SEQ ID NO: 3 indicates that a subject is susceptible and/or has NKTCL. The presence of both mutant JAK1 and JAK3 genes also indicate that a subject is at risk of developing and/or has NKTCL.
- The method may be performed on an isolated cell sample from the subject. The isolated cell sample may be from a blood and/or tumour sample. Accordingly, the method may further comprise providing an isolated cell sample from the subject for testing. The method may further comprise isolating nucleic acid molecules from the subject, blood sample and/or isolated cell sample for said testing. The isolated nucleic acid molecules may comprise genomic DNA or mRNA. In particular, the testing may be performed on genomic DNA, mRNA and/or cDNA.
- Any suitable technique may be employed for testing. For example, testing may be by sequence analysis, restriction fragment length polymorphism analysis, hybridization, polymerase chain reaction (PCR) and/or reverse transcription PCR. In particular, techniques such as Sanger sequencing and High resolution melt may be used for testing.
- In another aspect of the invention, there is provided a method for predicting Natural Killer T-Cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject, comprising testing for whether said subject expresses a wildtype or mutant JAK protein, wherein expression of a mutant JAK protein indicates that the subject is at risk of developing and/or has NKTCL.
- Any one or a combination of any of the JAK proteins may be tested. The JAK protein tested may be selected from the group consisting of JAK1, JAK2, JAK3 and TYK2. For example, the JAK3 and/or JAK1 proteins may be tested. In general, SEQ ID NO: 2 indicates a wildtype JAK3 protein. In one example, the presence of a mutant JAK3 gene comprising a substitution of A with V at amino acid 572 and/or a substitution of A with V at amino acid 573 of SEQ ID NO: 2 indicates that a subject is at risk of developing and/or has NKTCL.
- In general, SEQ ID NO: 4 indicates a wildtype JAK1 protein. In another example, the presence of a mutant JAK1 protein comprising a substitution of Y with D at amino acid 652 of SEQ ID NO: 4 indicates a subject at risk of developing and/or has NKTCL. The presence of both mutant JAK3 and JAK1 proteins also indicate a subject at risk of developing and/or has NKTCL.
- The method may be performed on an isolated blood and/or cell sample from the subject. The isolated cell sample may be from a tumour. Accordingly, the method may further comprise providing an isolated blood and/or cell sample from the subject for testing. The method may further comprise isolating proteins molecules from the subject, blood sample and/or isolated cell sample for said testing.
- Any suitable method may be used to detect whether the relevant wildtype and/or mutant JAK protein is expressed. For example, testing may be by protein sequencing and/or antibody detection. In particular, Enzyme-linked immunosorbent assay (ELISA) using at least one antibody with specificity for the relevant wildtype and/or mutant JAK protein may be used.
- In a second aspect of the invention, there is provided a method for screening for an agent capable of treating NKTCL, comprising:
-
- (a) providing a NKTCL cell line comprising at least one mutant JAK gene;
- (b) contacting the NKTCL cell line with the agent; and
- (c) determining the effect of the agent on the NKTCL cell line;
wherein the ability of the agent to reduce the viability, growth and/or multiplication and/or increase apoptosis of the NKTCL cell line may be indicative of the ability of the agent to treat NKTCL.
- In a third aspect of the invention, there is provided a method for screening for an agent capable of reducing the activity of at least one JAK protein, comprising:
-
- (i) providing a NKTCL cell line carrying at least one mutant JAK gene
- (ii) contacting the NKTCL cell line with the agent; and
- (iii) determining the effect of the agent on the NKTCL cell line;
- wherein the ability of the agent to reduce the viability, growth and/or multiplication and/or increase apoptosis of cell line is indicative of the ability of the candidate agent to reduce the activity of at least one JAK protein.
- The NKTCL cell line may carry any one or a combination of any of mutant JAK1, JAK2, JAK3 or TYK2 genes. For example, the NKTCL cell line may carry a mutant JAK3 gene and/or a mutant JAK1 gene. In particular, the mammalian NKTCL cell line may carry at least one of the following mutations:
-
- (i) a substitution of C with T at nucleotide 15792 of SEQ ID NO:1 (in the JAK3 gene);
- (ii) a substitution of C with T at nucleotide 15795 of SEQ ID NO:1 (in the JAK3 gene); and
- (iii) a substitution of T with G at nucleotide 124823 of SEQ ID NO:3 (in the JAK1 gene).
- According to a fourth aspect, the invention also relates to an NKTCL animal model comprising at least one mutant JAK gene. For example, the NKTCL animal model may comprise at least one mutation selected from the group consisting of mutant JAK1, JAK2, JAK3 and TYK2 genes. In particular, the NKTCL animal model comprises a mutant JAK3 gene and/or a mutant JAK1 gene. More in particular, the NKTCL animal model comprises at least one of the following mutations:
-
- (i) a substitution of C with T at nucleotide 15792 of SEQ ID NO: 1;
- (ii) a substitution of C with T at nucleotide 15795 of SEQ ID NO: 1; or
- (iii) a substitution of T with G at nucleotide 124823 of SEQ ID NO: 3.
- The NKTCL animal model may also be useful for screening candidate agents capable of treating NKTCL.
- According to a fifth aspect, there is provided a method of treating Natural Killer T-Cell Lymphoma (NKTCL) comprising administering at least one JAK inhibitor to a subject. Any suitable JAK inhibitor may be used. In another aspect of the invention, there is provided a use of at least one JAK inhibitor for the preparation of a medicament for the treatment of Natural Killer T-Cell Lymphoma (NKTCL). In another aspect of the invention, there is provided a JAK inhibitor for use in treating Natural Killer T-Cell Lymphoma (NKTCL). The JAK inhibitor may able to reduce the activity of JAK3 protein.
- For example, the JAK inhibitor may inhibit at least one of JAK1, JAK2, JAK3 and/or TYK2. Accordingly, the inhibitor may be a pan-JAK inhibitor. In one particular example, the JAK inhibitor may inhibit JAK3 and/or JAK1. More in particular, the JAK inhibitor may inhibit JAK3 or the JAK inhibitor may also inhibit JAK1.
- In a first particular example, the JAK inhibitor may comprise 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile (also known as CP-690,550). In a second particular example, may comprise (E)-2-cyano-3-(4-nitrophenyl)-N-((R)-1-phenylethyl)acrylamide (also known as WP-1034).
- The subject to whom the JAK inhibitor is administered may comprise a mammal. The subject may comprise a human. The subject may carry a homozygous or heterozygous mutation in at least one of the JAK genes/JAK proteins. For example, the subject may carry a homozygous or heterozygous mutation in JAK1/JAK1, JAK2/JAK2, JAK3/JAK3 and/or TYK2/TYK2. In particular, the subject may carry a homozygous or heterozygous mutation in JAK1/JAK1 and/or JAK3/JAK3. More in particular, the subject may have at least one mutation selected from the group consisting of JAK3-A572V, JAK3-A573V and JAK1-Y652D. However, the subject may also comprise a homozygous wildtype phenotype. The subject may have increased expression of any one of the JAK genes, its transcriptional and/or translational products (proteins), whether it carries a homozygous wildtype, heterozygous or homozygous mutant gene.
- CP-690,550 is a JAK inhibitor. It is known as Tofacitinib, Tasocitinib, or by the trade name XELJANZ. Its chemical name is 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile and its structural formula is:
- WP-1034 has been described as having proapoptotic and antileukemic activity in Acute Myeloid Leukemia (Faderl et al., Anticancer Research 25: 1841-1850 (2005)) (8). It is a member of the tyrphostin family of tyrosine kinase inhibitors, which has been predominantly studied as an inhibitor of the Jak-Stat pathway. Its chemical structure and name are as follows:
- Having now generally described the invention, the same will be more readily understood through reference to the following examples which are provided by way of illustration, and are not intended to be limiting of the present invention.
- The molecular pathogenesis of Natural-killer/T-cell lymphoma (NKTCL) is not well understood. Gene mutations causing NK/T-cell lymphoma have not been fully identified. In this study, Janus kinase 3 (JAK3) somatic activating mutations (A572V and A573V) were identified through whole-exome sequencing in two out of four NKTCL patients. Further validation of the prevalence of JAK3 mutations was determined by Sanger sequencing and High Resolution Melt (HRM) analysis in an additional 61 cases. In total, 23 of 65 (35.4%) cases harbored JAK3 mutations. Mutant NKTCL cell line harbouring JAK3 A572V mutation showed IL-2 independent growth and constitutive JAK3 and STAT5 phosphorylation suggesting its oncogenic role. Functional characterization of the JAK3 mutations support its involvement in cytokine-independent JAK/STAT constitutive activation leading to increased cell growth. These mutations may play a significant role in the pathogenesis of NKTCL. Moreover, treatment of both JAK3-mutant and wild-type NKTCL cell lines with a novel pan-JAK inhibitor, CP-690,550, resulted in dose dependent reduction of phosphorylated STAT5, reduced cell viability and increased apoptosis. CP-690,550 is a pan-JAK inhibitor, having an inhibitory effect on not just JAK3 but also JAK1. This may be important because in their function within the JAK-STAT signalling pathway system, JAK1 and JAK3 cross-talk and there may be some compensatory upregulation of one in response to inhibition of the other. For example, if JAK3 is inhibited, JAK1 may be upregulated so as to compensate for the reduced activity of JAK3, and this may preserve JAK-STAT signalling. The reverse may also apply. To take the example further, treatment of NKTCL using a pan-JAK inhibitor that is able to reduce the activity of not just JAK1 but JAK3 as well may be especially effective at inhibiting JAK-STAT signalling.
- Hence, targeting the deregulated JAK/STAT pathway could be a promising therapy for NKTCL patients. These findings have important implications for the management of NKTCL patients.
- Matched fresh-frozen tissue and peripheral blood samples were obtained from four consented patients with NKTCL. The inventors further identified paraffin-embedded tissue blocks from 61 patients with NKTCL for validation. The diagnosis of NKTCL was made according to the 2008 World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues (6). All samples were centrally reviewed by Singhealth hematopathologists. This study was approved by the SingHealth Centralized Institutional Review Board, Singapore.
- DNA of frozen tissue and paired blood samples was isolated using a DNeasy Blood and Tissue Mini Kit (Qiagen) and a QIAmp DNA Blood Midi Kit (Qiagen), respectively, according to manufacturer's instruction. For Formalin-Fixed Paraffin-Embedded (FFPE) samples, genomic DNA was extracted from one or two 10-μM slices from each sample, paraffin was removed by xylene, tissues were washed twice with 100% ethanol, followed by overnight proteinase K digestion. DNA was then extracted using a DNeasy Blood and Tissue Mini Kit (Qiagen).
- Genomic DNA of extracted from each sample was whole genome amplified with REPLI-g WGA Midi Kit (Qiagen). The coding exonic sequences of JAK1, JAK2, JAK3 and Tyk2 were sequenced by Sanger sequencing to detect mutations. Somatic origin of the mutations were confirmed when the mutations were only detected in the tumor but not in the paired blood sample.
- The mutation sequence information is provided below in Table 1 and in the accompanying genomic DNA, protein and cDNA sequence listings (SEQ ID No.:1 to SEQ ID No.: 6), with the following sequence identifiers:
-
- SEQ ID NO: 1—JAK3 Wildtype genomic DNA
- SEQ ID NO: 2—JAK3 Wildtype amino acid sequence
- SEQ ID NO: 3—JAK1 Wildtype genomic DNA
- SEQ ID NO: 4—JAK3 Wildtype amino acid sequence
- SEQ ID NO: 5—JAK3 Wildtype cDNA
- SEQ ID NO: 6—JAK1 Wildtype cDNA
-
TABLE 1 JAK1 and JAK3 Mutation Information Protein ORF1 cDNA Gene JAK1 Y652D6 T1954G T2203G2 T124823G4 JAK3 A572V7 C1715T C1815T3 C15792T5 JAK3 A573V7 C1718T C1818T3 C15795T5 Notes on Table 1: 1ORF: Open reading frame, coding region, starts from ATG 2NCBI Reference Sequence: NM_002227.2 (SEQ ID NO: 6) 3NCBI Reference Sequence: NM_000215.3 (SEQ ID NO: 5) 4NCBI Reference Sequence: NG_023402.1 (SEQ ID NO: 3) 5NCBI Reference Sequence: NG_007273.1 (SEQ ID NO: 1) 6NCBI Reference Sequence: NP_002218.2 (SEQ ID NO: 4) 7GenBank: AAC50950.1 (SEQ ID NO: 2) - High-resolution melt (HRM) and Sanger sequencing were used to confirm the JAK1 and JAK3 mutations and validate their prevalence in the NKTCL patient population. Combining both methods will greatly improve the precision of mutation detection in FFPE samples. The JAK2 V617F mutation was also sequenced with both methods. The sequences of primer sets used for validation are listed in Table 2 (see below) and included in the accompanying sequence listings under the corresponding identifiers.
- HRM Curve Analysis was used to discern the presence of the point mutations. SsoFast™ EvaGreen Supermix® (Bio Rad, Cat. No. 172-5200) was used for amplification of target DNA fragments encompassing the relevant mutations from genomic DNA samples. HRM primers were used at a final concentration of 600 nM and reactions were performed with BioRad CFX96 Real time PCR Detection System in replicates. The cycling and melting conditions were as follows: one cycle of 98° C. for 2 min; 39 cycles of 98° C. for 5 sec, 58° C. for 10 sec; one cycle of 95° C. for 30 min and a melt from 72° C. to 95° C. rising at 0.2° C./sec. The HRM curves were analyzed with the Biorad Precision Melt Analysis™ software. HRM difference curves deviating from the wild-type curve were considered to be harbouring a mutation.
- For Sanger sequencing, PCR was performed with Invitrogen Platinum Taq Polymerase (Cat. No. 10966-083) and cycled at 95° C. for 10 min; 39 cycles of 95° C. for 30 sec; 60° C. for 30 sec, 72° C. for 1 minute and a final extension of 72° C. for 10 min. Sequencing PCR was performed with ABI BigDye Terminator v3.1 (Cat. No. 4337457) and cycled at 96° C. for 1 min; 29 cycles of 96° C. for 10 sec; 50° C. for 5 sec & 60° C. for 4 min. The resulting products were run on ABI 3730 DNA Analyzer.
- NK-S1 is a cell line established from a previously described NKTCL xenograft (7). The xenograft was derived from metastatic tumor of the testis from the same patient found to have both JAK1 (Y652D) and JAK3 (A572V) mutations. NK-S1 was cultured for more than 60 passages in DMEM medium supplemented with antibiotics, heat-inactivated FBS (10%) and equine serum (ES) (10%). Phenotypic analysis showed surface CD3−CD56+, and Granzyme B+ by intracellular staining. NK-S1 NKTCL cell line was sequenced and confirmed to carry homozygous mutation for JAK3 A572V, as well as a mutation on JAK1 codon 652. KHYG-1 is an IL-2 dependent aggressive NK leukemia cell line obtained from the Japanese Collection of Research Bioresources, and it was cultured in RPMI medium supplemented with antibiotics, heat-inactivated FBS (10%), ES (10%) and 200 IU/ml of recombinant human IL-2 (Proleukin, Novartis)7. KHYG-1 was sequenced and found to be wild-type for JAK3 codon 572 and 573, and JAK1 codon 652 and 658. K562 (CCL-234, ATCC) is a chronic myeloid leukemia (CML) cell line positive for the BCR-ABL fusion gene.
- To study the sensitivity of NKTCL cell lines to CP-690,550 (Selleck Chemical, Cat. No. S5001), a pan-JAK inhibitor, cells were seeded at 2×104 cells/100 μL/well in 96-well plates and treated with CP-690,550 at various concentrations or with vehicle control. The viability was evaluated by MTS assay using a CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay Kit (Promega), absorbance was read at both 490 nm and 650 nm (as reference). The extent of drug-induced apoptosis was evaluated by Annexin V-FITC (BD Biosciences) staining. Acquisition of the data was performed on a FACSCalibur flow cytometer (BD Biosciences).
- Cells were harvested at indicated time intervals after incubation with or without recombinant human IL-2 (Proleukin, Novartis), or in the presence or absence of CP-690,550. Cells were washed with ice-cold phosphate buffer saline (PBS) and lysed in 50 μl of ice-cold RIPA buffer [25 mM Tris-HCL, pH 7.6, 150 mM NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 1× Phosphatase Inhibitor (Cat. No. 78420, Thermo Fisher Scientific), 1× Protease Inhibitor (Cat. No. 12978000, Roche Diagnostics) and 1 mM Sodium Orthovanadate]. Thereafter, cell lysates were sonicated twice on ice for 10 seconds, 20 Amp and agitated on ice for another 15 minutes. After centrifugation at 14,000 g for 15 minutes at 4° C., supernatants were removed and protein concentration was determined using Bio-Rad Protein assay (Cat. No. 500-0006, Bio-Rad Laboratories). Protein samples were separated on a 5% stacking and 8% resolving SDS-polyacrylamide gel using Mini-PROTEAN Tetra Electrophoresis System (Cat. No. 165-8006, Bio-Rad Laboratories) and transferred onto 0.45 μM nitrocellulose membrane (Cat No. 162-0115, Bio-Rad Laboratories) using Mini Trans-blot Electrophoretic Transfer Cell (Cat. No. 170-3930EDU, Bio-Rad Laboratories) at 100V for 120 minutes. Membranes were blocked with 5% Milk in PBST, followed by overnight incubation of rabbit anti-phospho-jak1 (Tyr 1022/1023) (Cat. No. 3331, Cell Signaling), rabbit anti-phospho-JAK3 (Tyr 980/981) (D44E3) (Cat. No. 5031, Cell Signaling), mouse anti-Phospho-Stat5 (Tyr 694) (Cat No. 9356, Cell Signaling) and rabbit anti-phospho-stat3 (Tyr 705) (D3A7) (Cat. No. 9145, Cell Signaling) in 5% BSA and 5 mM sodium orthovanadate in PBST. were visualized using enhanced chemiluminescence (ECL) (Cat. No. 3407, Thermo Fisher Scientific, and Cat. No. RPN 2132, Amersham). Antibody for Jak1 (6G4) (Cat. No. 3344, Cell Signaling), Jak3 (Cat. No. 3775, Cell Signaling), Stat5 (Cat. No. 9363, Cell Signaling) and β-actin (Cat. No. A1978, Sigma) were used to detect unphosphorylated proteins or as a loading control. All antibodies were used at the recommended dilutions.
- Sanger sequencing was used to sequence the exonic regions of JAK1, JAK2, JAK3 and Tyk2 in fresh frozen tumor and blood specimens from four patients with Extra nodal NKTCL. Two JAK3 mutations, A572V (p.Ala572Val, c.1715C>T) and A573V (p.Ala573Val, c.1718C>T), and a novel JAK1 mutation, Y652D (p.Tyr652Asp, c.1954T>G) were identified. Interestingly, JAK3 A572V and JAK1 Y652D mutations were found on the same sample. Both JAK3 mutations are both located at exon 12 on the JH2 pseudokinase domain (
FIG. 1 a), which is known to have an auto-inhibitory effect on the JH1 kinase domain. All three missense mutations identified in JAK1 and JAK3 were confirmed to be somatic in origin and predicted by Polyphen to be probably damaging. - Mutations identified were validated in FFPE samples of additional 61 patients with ENKTCL to confirm their prevalence. From this validation study, another 21 patients with JAK3 mutations were identified by Sanger sequencing. In total, out of 65
NKTCL patients 23 patients (35.4%) were found with JAK3 mutations (FIG. 1 b). High Resolution Melt (HRM) analysis was performed on 40 FFPE samples and 14 JAK3 mutants were detected (35%). Amongst the 23 patients with JAK3 mutations, there were 17 heterozygous A572V, two homozygous A572V, two heterozygous A573V mutants, one homozygous A573V mutant and one patient had both an A572V and A573V heterozygous mutations (FIG. 1 c-h). No additional JAK1 Y652D mutant was found. In addition, no patients were found with the JAK2 V617F (p.Val617Phe or c.1849G>T) mutation, which is recently found to be present in a large proportion of patients with classic BCR/ABL-negative chronic myeloproliferative disorders and several patients with other clonal hematological cancers such as myelodysplastic syndrome and acute myeloid leukemia. - IL-2 is an essential cytokine required for the proliferation and activation of NK cells (4). JAK1 and JAK3 mediate IL-2 receptor signaling through phosphorylation of STAT transcription factors (5). In line with the functional importance of the activating JAK3 mutations identified, we tested if JAK3 mutations could confer IL-2 independent growth to the NKTCL cell line (NK-S1) that harbors a homozygous JAK3A572V mutation. JAK-mutant (NK-S1) cells showed IL-2 independent growth (
FIG. 3 ) and constitutive phosphorylation of both JAK3 and STAT5 (FIG. 2 a). In contrast, JAK3-wild type KHYG-1 cells were clearly IL-2 dependent (FIGS. 3 and 2 a). Importantly, NK-S1 cells treated with JAK3 siRNAs exhibited a significant reduction in cell proliferation and also decreased autophosphorylation of JAK3 and STAT5, compared with cells treated with control siRNAs (FIG. 4A ). Reciprocally, KHYG-1 cells transiently over-expressing a mutated JAK3 (JAK3A572V) cDNA demonstrated IL-2 independent proliferation and autophosphorylation of JAK3 and STAT5 (FIG. 4B ). These results indicate that the JAK3 activating mutations are gain of function alleles and contribute to the constitutive activity of the JAK/STAT pathway in an IL-2 independent manner. - This study demonstrated that JAK mutations confers cytokine independent growth in a NKTCL cell line established from xenograft derived from patient sample harboring both JAK3 A572V and JAK1 Y652D mutation. NK-S1 showed IL-2 independent growth (
FIG. 3 ), constitutive JAK3 and STAT5 phosphorylation (FIG. 2 a) in contrast to the wild-type KHYG-1, which was tested not to carry JAK1 and JAK3 mutations identified (FIG. 2 a). - The ability of CP-690,550, a pan-JAK inhibitor, to suppress the JAK-STAT pathway, was evaluated. Because activated JAK proteins directly phosphorylate STAT proteins, the JAK-mutated cell line (NK-S1) and the wild-type NKTCL cell line (KHYG-1) were treated with increasing concentrations of CP-690,550 and analyzed the pSTAT5 by immunoblotting (
FIG. 2 b). Both the NK-S1 and KHYG-1 cell lines showed a dose-dependent reduction of pSTAT5 (FIG. 2 a) and reduced cell viability (FIG. 2 b) upon treatment with the inhibitor. CP-690,550 did not inhibit pSTAT5 in the control K562 cell lines since its STAT5 phosphorylation is independent of activated JAK3 (FIG. 2 b). The reduced viability of NK-S1 correlated with increased apoptosis as shown by Annexin V staining (FIG. 2 c). - In summary, through exonic sequencing of Janus kinases (JAK) of Natural-killer/T-cell lymphoma (NKTCL) JAK3 A572 and A573V and JAK1 Y652D mutations have been identified in NKTCL patients, and the prevalence of JAK3 mutations was validated to be 35.4%. A mutant NKTCL cell line harboring JAK3 A572V mutation showed IL-2 independent growth and constitutive JAK3 and STAT5 phosphorylation suggesting an oncogenic role for mutations in the corresponding nucleic acid domain. In vitro study suggests that pan-Jak inhibitor could be a new therapeutic agent for NKTCL patients. CP-690,550, a pan-JAK-inhibitor, was shown to reduce cell viability and cause apoptosis in both JAK3 wild-type (KHYG-1) and mutant (NK-S1) cell lines. KHYG-1 is an IL-2 dependent NKTCL cell line, thus its sensitivity to pan-JAK inhibitor.
-
- 1. Kwong Y L, Anderson B O, Advani R, Kim W S, Levine A M, Lim S T. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. The lancet oncology 2009; 10(11): 1093-1101.
- 2. Au W Y, Ma S Y, Chim C S, Choy C, Loong F, Lie A K et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 2005; 16(2): 206-214.
- 3. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26(25): 4124-4130.
- 4. Suzuki R, Handa K, Itoh K, Kumagai K. Natural killer (NK) cells as a responder to interleukin 2 (IL 2). I. Proliferative response and establishment of cloned cells. J Immunol 1983; 130(2): 981-987.
- 5. Lu L, Zhu J, Zheng Z, Yan M, Xu W, Sun L et al. Jak-STAT pathway is involved in the induction of TNF-beta gene during stimulation by IL-2. European journal of immunology 1998; 28(3): 805-810.
- 6. Campo E, Swerdlow S H, Harris N L, Pileri S, Stein H, Jaffe E S. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2008; 117(19): 5019-5032.
- 7. Loong S L, Hwang J S, Lim S T, Yap S P, Tao M, Chong T W et al. An Epstein-Barr virus positive natural killer lymphoma xenograft derived for drug testing. Leukemia & lymphoma 2008; 49(6): 1161-1167.
- 8. Faderl et al., WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML). Anticancer Research 25: 1841-1850 (2005)
Claims (30)
1. A method for predicting Natural Killer T-Cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject, comprising testing for the genotype of said subject for at least one JAK gene or testing for whether said subject expresses a wildtype or mutant JAK protein, wherein the presence of a mutant JAK gene indicates that a subject is at risk of developing and/or has NKTCL.
2. The method according to claim 1 , wherein:
when the method comprises testing for the genotype of said subject for at least one JAK gene, the method comprises testing for the genotype of said subject for at least one of JAK1, JAK2, JAK3 and/or TYK2 genes; and
when the method comprises testing for whether said subject expresses a wildtype or mutant JAK protein, the method comprises testing for whether said subject expresses wildtype and/or at least one mutant JAK1, JAK2, JAK3 and/or TYK2 protein.
3. (canceled)
4. The method according to claim 1 , wherein:
a wildtype JAK3 gene comprises SEQ ID NO: 1 and the mutant JAK3 gene comprises a substitution of C with T at nucleotide 15792 and/or a substitution of C with T at nucleotide 15795 of SEQ ID NO: 1; and/or
a wildtype JAK1 gene comprises SEQ ID NO: 3 and the mutant gene comprises a substitution of T with G at nucleotide 124823 of SEQ ID NO:3.
5. (canceled)
6. The method according to claim 1 , further comprising providing an isolated blood and/or cell sample from the subject for said testing.
7. The method according to claim 6 , wherein
when the method comprises testing for the genotype of said subject for at least one JAK gene, the method further comprises isolating nucleic acid molecules from the subject for said testing; and
when the method comprises testing for whether said subject expresses a wildtype or mutant JAK protein, the method further comprises isolating at least one protein from the subject for said testing.
8. (canceled)
9. The method according to claim 1 , wherein when the method comprises testing for the genotype of said subject for at least one JAK gene,
said testing is performed on genomic DNA, mRNA and/or cDNA; and/or
said testing comprises sequence analysis, restriction fragment length polymorphism analysis, hybridization, polymerase chain reaction (PCR), or reverse transcription PCR
10-17. (canceled)
18. The method according to claim 1 , wherein when the method comprises testing for whether said subject expresses a wildtype or mutant JAK protein, the testing comprises protein sequencing and antibody detection methods.
19. A method for screening for an agent capable of treating NKTCL, or for an agent capable of reducing the activity of at least one JAK protein,
the method comprising:
(i) providing a NKTCL cell line comprising at least one mutant JAK gene;
(ii) contacting the NKTCL cell line with the agent; and
(iii) determining the effect of the agent on the mammalian NKTCL cell line;
wherein the ability of the agent to reduce the viability, growth and/or multiplication and/or increase apoptosis of the NKTCL cell line is indicative of the ability of the agent to treat NKTCL, or to reduce the activity of at least one JAK protein.
20. (canceled)
21. The method according to claim 19 , wherein the NKTCL cell line carries at least one of mutant JAK1, JAK2, JAK3 and/or TYK2 genes.
22. (canceled)
23. The method according to claim 19 , wherein the NKTCL cell line carries at least one of the following JAK mutations:
(i) a substitution of C with Tat nucleotide 15792 of SEQ ID NO: 1;
(ii) a substitution of C with Tat nucleotide 15795 of SEQ ID NO: 1; and
(iii) a substitution of T with G at nucleotide 124823 of SEQ ID NO: 3.
24. An NKTCL animal model comprising at least one mutant JAK gene.
25. The NKTCL animal model according to claim 24 , comprising at least one of mutant JAK1, JAK2, JAK3 and/or TYK2 genes.
26. (canceled)
27. The NKTCL animal model according to claim 24 , comprising at least one of the following mutations:
(i) a substitution of C with Tat nucleotide 15792 of SEQ ID NO: 1;
(ii) a substitution of C with Tat nucleotide 15795 of SEQ ID NO: 1; or
(iii) a substitution of T with G at nucleotide 124823 of SEQ ID NO: 3.
28. A method of treating Natural Killer T-Cell Lymphoma (NKTCL) comprising administering at least one JAK inhibitor to a subject.
29. The method according to claim 28 , wherein the JAK inhibitor inhibits at least one of JAK1, JAK2, JAK3 and/or TYK2 proteins.
30-32. (canceled)
33. The method according to claim 28 , wherein the JAK inhibitor comprises 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile (CP-690,550) and/or (E)-2-cyano-3-(4-nitrophenyl)-N-((R)-1-phenylethyl)acrylamide (WP-1034).
34-35. (canceled)
36. The method according to claim 28 , wherein the subject comprises a mammal.
37. (canceled)
38. The method according to claim 28 , wherein the subject with at least one mutation selected from the group consisting of JAK3-A572V, JAK3-A573V and/or JAK1-Y652D.
39-56. (canceled)
57. The method according to claim 1 , wherein:
the wildtype JAK3 protein comprises SEQ ID NO:2 and the mutant JAK3 protein comprises a substitution of A with V at amino acid 572 and/or a substitution of A with V at amino acid 573 of SEQ ID NO:2; and/or
the wildtype JAK1 protein comprises SEQ ID NO: 4 and the mutant JAK1 protein comprises a substitution of Y with D at amino acid 652 of SEQ ID NO:4.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG2011088002 | 2011-11-25 | ||
SG201108800-2 | 2011-11-25 | ||
PCT/SG2012/000444 WO2013077814A2 (en) | 2011-11-25 | 2012-11-26 | Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SG2012/000444 A-371-Of-International WO2013077814A2 (en) | 2011-11-25 | 2012-11-26 | Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/174,578 Continuation US10378062B2 (en) | 2011-11-25 | 2016-06-06 | Natural-killer/T-cell lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150292022A1 true US20150292022A1 (en) | 2015-10-15 |
Family
ID=54257023
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/360,804 Abandoned US20150292022A1 (en) | 2011-11-25 | 2012-11-26 | Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy |
US15/174,578 Expired - Fee Related US10378062B2 (en) | 2011-11-25 | 2016-06-06 | Natural-killer/T-cell lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/174,578 Expired - Fee Related US10378062B2 (en) | 2011-11-25 | 2016-06-06 | Natural-killer/T-cell lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy |
Country Status (6)
Country | Link |
---|---|
US (2) | US20150292022A1 (en) |
EP (1) | EP2782562B1 (en) |
JP (1) | JP2015505669A (en) |
CN (1) | CN104220051B (en) |
SG (2) | SG10201605729TA (en) |
WO (1) | WO2013077814A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6416508B2 (en) * | 2014-06-05 | 2018-10-31 | 公益財団法人がん研究会 | Examination method of NK / T cell lymphoma |
MX2019006597A (en) * | 2016-12-09 | 2019-10-15 | Onkimmune Ltd | Improved nk-based cell therapy. |
SG11202003127WA (en) * | 2017-10-06 | 2020-05-28 | Singapore Health Serv Pte Ltd | Methods for treating lymphomas |
CN108841869B (en) * | 2018-05-31 | 2022-05-06 | 上海交通大学医学院附属瑞金医院 | Construction method and application of zebra fish NK/TCL tumor model |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60129926T2 (en) * | 2000-01-24 | 2008-06-19 | Genzyme Corp., Cambridge | INHIBITORS OF THE JAK / STAT PATH AND ITS USE IN TREATING GENERAL PRIMARY OSTEOARTHRITIS |
EP1984523A4 (en) * | 2006-01-20 | 2010-03-03 | Cell Signaling Technology Inc | Mutant jak3 kinase in human leukemia |
-
2012
- 2012-11-26 CN CN201280067986.3A patent/CN104220051B/en not_active Expired - Fee Related
- 2012-11-26 SG SG10201605729TA patent/SG10201605729TA/en unknown
- 2012-11-26 WO PCT/SG2012/000444 patent/WO2013077814A2/en active Application Filing
- 2012-11-26 JP JP2014543455A patent/JP2015505669A/en active Pending
- 2012-11-26 EP EP12799341.8A patent/EP2782562B1/en not_active Not-in-force
- 2012-11-26 SG SG11201402611WA patent/SG11201402611WA/en unknown
- 2012-11-26 US US14/360,804 patent/US20150292022A1/en not_active Abandoned
-
2016
- 2016-06-06 US US15/174,578 patent/US10378062B2/en not_active Expired - Fee Related
Non-Patent Citations (5)
Title |
---|
Cornejo et al (Blood, 2009, 113(12): 2746-2754) * |
Kiyoi et al (Leukemia, 2007, 21: 574-576) * |
Mella et al (Human Mutation, 2001, 18(4): 1-7) * |
Percy et al (Hematological Oncology, 2005, 25: 91-93) * |
Schumacher et al (Hum Genet, 2000, 106: 73-79) * |
Also Published As
Publication number | Publication date |
---|---|
JP2015505669A (en) | 2015-02-26 |
WO2013077814A2 (en) | 2013-05-30 |
EP2782562A2 (en) | 2014-10-01 |
SG11201402611WA (en) | 2014-06-27 |
CN104220051A (en) | 2014-12-17 |
US10378062B2 (en) | 2019-08-13 |
SG10201605729TA (en) | 2016-08-30 |
EP2782562B1 (en) | 2016-12-21 |
CN104220051B (en) | 2017-04-19 |
US20170029899A1 (en) | 2017-02-02 |
WO2013077814A3 (en) | 2013-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tibarewal et al. | PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumor-suppressing phenotype, but not with AKT activity | |
US7781199B2 (en) | Identification of a JAK2 mutation involved in Vaquez Polyglobulia | |
US10378062B2 (en) | Natural-killer/T-cell lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy | |
Richter et al. | Effects of altered expression and activity levels of CK1δ and ɛ on tumor growth and survival of colorectal cancer patients | |
Kim et al. | Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease | |
Frietsch et al. | LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia | |
RU2663701C2 (en) | Markers associated with wnt inhibitors | |
Roider et al. | The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial | |
Fukumura et al. | STK10 missense mutations associated with anti-apoptotic function | |
EP2870261B1 (en) | Biomarkers associated with cdk inhibitors | |
Wasik et al. | Clinical and functional impact of recurrent S1PR1 mutations in mantle cell lymphoma | |
Park et al. | The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51 | |
Park et al. | Single nucleotide polymorphisms in DNA repair genes and prostate cancer risk | |
Rodríguez-Hernández et al. | VRK2 identifies a subgroup of primary high-grade astrocytomas with a better prognosis | |
EP2732287B1 (en) | Methods of prognosing chronic lymphocytic leukemia | |
WO2020104762A1 (en) | Biomarkers and uses of pnp inhibitors | |
De Rosa et al. | PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer | |
Shiuan | The EPHA2/Ephrin-A1 Axis Regulates Host-Tumor Interactions | |
US20150240317A1 (en) | Functional genomics screening platform for head and neck cancer | |
AU2006300760B2 (en) | A diagnostic marker and therapeutic target for cancer | |
Hughes | Overexpression of Adenylate Cyclase Isoforms Alters Cell Signaling Pathways in NF1-Null Malignant Peripheral Nerve Sheath Tumors | |
Huang et al. | Inhibition of CDK4 as a potential therapy for natural killer cell lymphoma with MYC overexpression | |
Wei | The Oncogenic Role of the Protein Tyrosine Phosphatase 4A3 (PTP4A3 Or PRL-3) in T-cell Acute Lymphoblastic Leukemia | |
Chow | Regulation and Signaling Mechanisms of ROR1 in B cell Acute Lymphoblastic Leukemia | |
Leblanc | Targeting sphingolipid metabolism in large granular lymphocyte leukemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SINGAPORE HEALTH SERVICES PTE LTD, SINGAPORE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TEH, BIN TEAN;LIM, SOON THYE;REEL/FRAME:033108/0743 Effective date: 20130103 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |